Valuation: RAPT Therapeutics, Inc.

Market Cap 939M 834M 773M 704M 1.33B 89.08B 1.35B 9.29B 3.64B 46.48B 3.52B 3.45B 148B P/E 2023
-8.16x
P/E 2024 -0.5x
Enterprise Value 712M 633M 587M 534M 1.01B 67.57B 1.02B 7.05B 2.76B 35.26B 2.67B 2.62B 112B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
96.87%
Yield 2023 *
-
Yield 2024 -
1 day+0.07%
Current year+71.30%
Current year 29.77
Extreme 29.77
58.02
1 year 25.5
Extreme 25.5001
58.02
3 years 5.67
Extreme 5.6652
218.8
5 years 5.67
Extreme 5.6652
325.92
10 years 5.67
Extreme 5.6652
409.68
Manager TitleAgeSince
President - 02/03/2026
Treasurer - 02/03/2026
Director TitleAgeSince
Director/Board Member - 02/03/2026
Director/Board Member - 02/03/2026
Date Insider Type Main position Quantity % Market Cap. Importance
03/03/26 Tender

Chief Technology Officer

164,742 0.5945%
03/03/26 Tender

Chief Financial Officer

205,703 0.7423%
03/03/26 Tender

Director

59,858 0.2160%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-.--%+100.55%-41.13% 1.79B
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -1.66%-1.49%+49.05%+73.02% 37.37B
Weighted average by Cap. -2.29%-1.20%+43.84%+87.95%

Financials

2023 2024
Net sales - -
Net income -117M -104M -96.23M -87.55M -165M -11.08B -168M -1.16B -454M -5.78B -438M -429M -18.44B -130M -115M -107M -97.35M -184M -12.33B -187M -1.29B -504M -6.43B -487M -477M -20.5B
Net Debt -152M -135M -125M -114M -215M -14.42B -218M -1.5B -590M -7.53B -570M -558M -23.99B -227M -201M -187M -170M -320M -21.5B -326M -2.24B -880M -11.22B -850M -832M -35.77B
Projected Income Statement - Annual - RAPT Therapeutics, Inc.
Logo RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Employees
60
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RAPT Stock